CD163 and metabolic dysfunction-associated steatohepatitis: MAFLD patients displayed similar sCD163 levels to the control group [0.322 mg/L (0.034–1.374)], but, as expected, those patients classified as NASH displayed higher sCD163 values [0.403 mg/L (0.034–1.374), p = 0.019] (Fig 1B).